Physiomics Plc · LSE:PYC

Physiomics — BioTrinity 2019

10 slides from Physiomics's conference presentation, Apr 30, 2019

  1. Slide 1: Introduction to Physiomics

    Introduction to Physiomics BioTrinity London, 30 April 2019 Copyright © Physiomics Plc 2019 - www.physiomics.co.uk

  2. Slide 2: Physiomics is a consultancy focused on modelling cancer

    Physiomics is a consultancy focused on modelling cancer Knowledge of PK/ PD modelling cancer using Virtual Tumour™ Ability to access Understanding of AI/ and curate data machine learning Slide 2 Copyright © Physiomics Plc 2019 - www.physiomics.co.uk

  3. Slide 3: Dual company focus

    Dual company focus Supporting oncology R&D Personalised oncology • Analytical and modelling support • Grant funded by Innovate UK for oncology pre-clinical • Potential to predict toxicity development and response to treatment for individuals or groups • Potential applications in real world or trials

  4. Slide 4: Completed over 70 commercial and grant funded projects

    Completed over 70 commercial and grant funded projects Big pharma Merck, MSD, Lilly, Bayer and others Grants Innovate UK, EU-FP6 (TEMPO), Carbon Trust (Green Biologics lead) 70projects completed Biotech/ Midcap CellCentric, Convert Pharma, Cyclacel, Sareum, and others Academic Medicines Discovery Ca

  5. Slide 5: How we support development

    How we support development Recommend efficacy/ toxicity trade-offs ✓ Recommend additional experiments to confirm and refine hypotheses if desired ✓ Recommend combination partner agent for proprietary in-house asset ✓ Assess efficacy of existing assets in new indications ✓ Predict biologically effect

  6. Slide 6: Case study: Physiomics supports CellCentric first in man studies

    Case study: Physiomics supports CellCentric first in man studies • CellCentric is developing a novel small molecule for prostate and other cancers • Physiomics supported CellCentric with modelling and analysis in support of FIM dosing and scheduling • Further supported FIM dosing and scheduling for

  7. Slide 7: Case study: Using Virtual Tumour to model response rates following radiotherapy

    Case study: Using Virtual Tumour™ to model response rates following radiotherapy • Physiomics developed a sophisticated model of radiotherapy combination treatment in clinical setting with an undisclosed client • Poster based on use of model with literature data for combination RT/ cisplatin treatme

  8. Slide 8: Case study: Innovate UK funded personalised oncology project

    Case study: Innovate UK funded personalised oncology project • Literature describes ‘underdosing’ and ‘overdosing’ of various cancer drugs due to inter-patient variability • Focusing on docetaxel in prostate cancer Physiomics developed a personalised treatment tool to support dosing decisions • Reli

  9. Slide 9: Forging links with industry and academia

    Forging links with industry and academia Note: Logos represent selected current and historical partners Slide 9 Copyright © Physiomics Plc 2019 - www.physiomics.co.uk

  10. Slide 10: Thanks for your attention

    Thanks for your attention Contact us at info@physiomics.co.uk Visit our website at www.physiomics.co.uk Slide 10

Physiomics — BioTrinity 2019 on 6ix